吃饭吃完了，发一个abus和sb9200合作消息

newchinabok

http://ir.springbankpharm.com/ne ... nir_news_date_value[min]=2018

newchinabok

Spring Bank and Arbutus Biopharma Announce Preclinical Collaboration in Study of Chronic Hepatitis B
HOPKINTON, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc.  (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, and Arbutus Biopharma Corporation  (NASDAQ:ABUS) today announced an agreement to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV) involving the co-administration of Spring Bank’s SB 9200, an orally-available selective immune-modulator, and Arbutus Biopharma’s AB-423, a capsid assembly inhibitor. SB 9200 and AB-423 are each investigational compounds currently under development by the respective companies for the treatment of chronic HBV.
“The preclinical study of the combination of SB 9200 and AB-423 is the first step in evaluating how a capsid assembly inhibitor can be combined with an oral immune-modulator in the treatment of chronic HBV and potentially lead to novel combination therapeutic strategies for patients with chronic HBV," stated Nezam Afdhal, M.D., chief medical officer of Spring Bank. “We look forward to working with the team at Arbutus as we advance this collaboration.”
About SB 9200
SB 9200 is Spring Bank’s novel small molecule, orally-available selective immune-modulator compound being developed as both monotherapy and combination therapy as a backbone for the treatment of chronic HBV and other viral diseases. SB 9200 is currently being studied in the ACHIEVE Phase II global trial. Part A of the ACHIEVE study is a placebo-controlled, sequential cohort, double blind trial to evaluate increasing doses of SB 9200 as monotherapy for 12 weeks followed by tenofovir disoproxil fumarate 300mg (Viread® Gilead Sciences Inc.) for a further 12 weeks. Part B of the ACHIEVE study will evaluate SB 9200 in combination with tenofovir and as monotherapy versus tenofovir monotherapy after the optimal doses of SB 9200 are determined in Part A.

齐欢畅

View printer-friendly version
<< Back
Spring Bank and Arbutus Biopharma Announce Preclinical Collaboration in Study of Chronic Hepatitis B
HOPKINTON, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, and Arbutus Biopharma Corporation (NASDAQ:ABUS) today announced an agreement to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV) involving the co-administration of Spring Bank’s SB 9200, an orally-available selective immune-modulator, and Arbutus Biopharma’s AB-423, a capsid assembly inhibitor. SB 9200 and AB-423 are each investigational compounds currently under development by the respective companies for the treatment of chronic HBV.
“The preclinical study of the combination of SB 9200 and AB-423 is the first step in evaluating how a capsid assembly inhibitor can be combined with an oral immune-modulator in the treatment of chronic HBV and potentially lead to novel combination therapeutic strategies for patients with chronic HBV," stated Nezam Afdhal, M.D., chief medical officer of Spring Bank. “We look forward to working with the team at Arbutus as we advance this collaboration.”
About SB 9200
SB 9200 is Spring Bank’s novel small molecule, orally-available selective immune-modulator compound being developed as both monotherapy and combination therapy as a backbone for the treatment of chronic HBV and other viral diseases. SB 9200 is currently being studied in the ACHIEVE Phase II global trial. Part A of the ACHIEVE study is a placebo-controlled, sequential cohort, double blind trial to evaluate increasing doses of SB 9200 as monotherapy for 12 weeks followed by tenofovir disoproxil fumarate 300mg (Viread® Gilead Sciences Inc.) for a further 12 weeks. Part B of the ACHIEVE study will evaluate SB 9200 in combination with tenofovir and as monotherapy versus tenofovir monotherapy after the optimal doses of SB 9200 are determined in Part A.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body’s immune response to viral infections. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body’s immune response through its mechanisms of action to fight viral infections such as HBV.
Spring Bank Safe Harbor Statement:
Any statements in this press release about Spring Bank’s future expectations, plans and prospects, including statements about Spring Bank’s financial prospects, future operations and sufficiency of funds for future operations, clinical development of Spring Bank’s product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Spring Bank and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank’s product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other risks and uncertainties identified under the heading "Risk Factors" included in the Company’s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission (SEC) on December 16, 2016, and in other filings Spring Bank makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date subsequent to the date hereof.
Contact:

Jon Freve
Chief Financial Officer
Spring Bank Pharmaceuticals
(508) 473-5993
[email protected]
Primary Logo

齐欢畅

查看打印版本
< <回来
春季银行和杨梅生物制药宣布临床协作研究慢性乙型肝炎
数据质量。,2016年12月19日(全球通讯社)—春季银行制药公司。(纳斯达克:SBPH)临床分期生物制药公司开发新疗法治疗病毒感染,癌症,和炎性疾病杨梅生物制药公司(纳斯达克:离合器)今天宣布一项协议来执行协作的临床前研究在慢性乙型肝炎病毒(HBV)涉及9200年春天的合并施打银行的某人,一个orally-available选择性immune-modulator,杨梅生物制药的ab - 423,一个衣壳组装抑制剂。 某人9200和ab - 423是每个临床实验的化合物各自的公司目前正在开发的治疗慢性乙型肝炎病毒。
的临床前研究的结合某人9200和ab - 423是第一步在评估如何结合一种衣壳组装抑制剂口服immune-modulator治疗慢性乙肝病毒和可能导致小说结合慢性乙肝患者的治疗策略,”声明Nezam Afdhal,医学博士 首席医疗官的春季银行。 “我们期待着与我们推动这种合作的团队在杨梅。”
某人9200
某人9200年春季银行的新型小分子,orally-available选择性immune-modulator化合物被开发作为单药治疗和联合治疗作为治疗慢性乙肝病毒的骨干和其它病毒性疾病。 某人9200目前在全球实现第二阶段试验进行研究。 部分实现的研究是一种安慰剂对照,顺序队列,双盲试验来评估增加剂量的某人9200年作为单药治疗12周之后,泰诺福韦disoproxil延胡索酸酯300毫克(韦®吉利德科技公司。)进一步12周。 B部分实现的研究将评估某人9200结合替诺福韦和单一疗法与替诺福韦单药治疗后的最佳剂量某人9200部分决定。
关于春季银行制药
春季银行制药是一个临床分期生物制药公司从事小说类的发现和开发治疗使用其专有的小分子核酸杂交,或SMNH化学平台。 SMNH化合物是小片段的核酸,公司设计选择性地目标和调节特定蛋白质的活动涉及多种疾病。 该公司正在开发其最先进SMNH产品候选人,某人9200年病毒性疾病的治疗,包括乙型肝炎病毒。 某人9200年设计了选择性地激活感染细胞细胞内蛋白质,维生素a acid-inducible基因1,或rig - i和nucleotide-binding寡聚化domain-containing蛋白质2,或NOD2,已涉及身体对病毒感染的免疫反应。春季银行相信某人9200年可能发挥重要作用在抗病毒疗法通过调节人体的免疫反应机制的行动来对抗乙肝病毒等病毒感染。
春季银行安全港声明:
任何声明在本新闻稿中关于春天银行的未来预期,计划和前景,包括语句对春季银行的财务前景,未来的未来业务操作和充足的资金,春天的临床开发银行的产品候选人,期望对未来临床试验和未来预期和计划和前景春季银行和其他语句包含单词“相信”,“预期”,“估计”,“期望”,“计划”,“计划”,“预测”,“项目”,“目标”“可能”“潜力,”“将”“会”“可能”“应该”“继续,”和类似的表情,构成前瞻性陈述的意义在1995年私人证券诉讼改革法案。 实际结果可能不同物质与等前瞻性陈述表示的各种重要因素的结果,包括春季银行的现金资源是否足以为其持续经营的时间预期; 是否在临床试验中获得的结果将表明在未来的临床试验结果; 春季银行产品候选人是否会提前通过临床试验过程及时; 这些试验的结果是否会保证提交的批准美国食品和药物管理局或同等外国监管机构; 春季银行产品候选人是否会得到及时的基础上获得监管机构的批准或; 是否,如果产品候选人获得批准,他们将成功地分布和销售; 和其他风险和不确定性识别标题下的“风险因素”包括在该公司的注册声明形式向s - 1证券交易委员会(证券交易委员会)2016年12月16日和其他文件春季银行使与证券交易委员会的时候。 此外,这个新闻稿的前瞻性陈述包括代表春天银行截至日期规定的看法。春季银行预计,随后的事件和发展将导致春季银行的看法改变。 然而,尽管春季银行可以选择更新这些前瞻性陈述在将来的某个时候,春季银行明确放弃任何义务这么做。 这些前瞻性陈述不应该依赖银行代表春天的看法的任何日期之后的日期。
联系人:Jon Freve首席财务官春季银行制药(508)473 - [email protected]
Primary Logo

齐欢畅

走联合用药之路是正解。